Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest PTC Therapeutics Stories

2013-08-29 16:25:30

SOUTH PLAINFIELD, N.J., Aug. 29, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in following conferences in September: -- Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will participate in a panel at the Citi 8(th) Annual Biotech Conference in Boston on Wednesday, September 4 at 10:00 a.m. ET. The panel is titled Born to Run: RNA Therapies Racing to the Market. -- Shane Kovacs,...

2013-08-12 16:26:08

-- Conference call to be held today at 4:30 p.m. ET -- SOUTH PLAINFIELD, N.J., Aug. 12, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "The first half of the...

2013-08-08 08:30:29

- PTC to Receive $10 Million Payment from Roche - SOUTH PLAINFIELD, N.J., Aug. 8, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO) "We are excited about this important achievement in our...

2013-08-06 08:33:47

SOUTH PLAINFIELD, N.J., Aug. 6, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs, Chief Financial Officer of PTC Therapeutics will present a company overview at the Wedbush Securities Life Sciences Management Access Conference in New York City on Tuesday, August 13, 2013 at 1:20 pm EDT. In addition, Dr. Stuart Peltz, Chief Executive Officer will participate in a panel discussion entitled "Leaders in DMD and Rare Disease" from 11:30 am-12:40...

2013-08-05 08:27:43

SOUTH PLAINFIELD, N.J., Aug. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will report financial results for the second quarter ended June 30, 2013 following the close of market on Monday, August 12, 2013. PTC management will host a conference call and webcast to discuss financial results and provide a corporate update on Monday, August 12, 2013 at 4:30 p.m. (ET). The call can be accessed by dialing 877-303-9216 (domestic) or...

2013-06-20 08:25:59

SOUTH PLAINFIELD, N.J., June 20, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the...

2013-06-03 08:28:21

SOUTH PLAINFIELD, N.J., June 3, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Shane Kovacs as Chief Financial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Kovacs will be responsible for all finance-related activities at PTC. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "We are excited to welcome Shane as a member of our senior management team," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. "His...

2013-04-23 08:34:09

SOUTH PLAINFIELD, N.J., April 23, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "It is an exciting opportunity to join PTC," stated Mr. Rothera....

2013-03-07 12:27:23

-Funds to support Phase 3 confirmatory trials of ataluren- SOUTH PLAINFIELD, N.J., March 7, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P. Joining Brookside as new investors in this financing are Adage Capital Management, Jennison Associates L.L.C. (on behalf of fund clients), Longwood Fund and additional top-tier institutional investors. In conjunction with the...

2012-11-06 08:28:13

SOUTH PLAINFIELD, N.J., Nov. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty pharmaceutical company developing therapies for patients with rare disorders and significant medical needs. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "We are...